Skip to content
Screener

Fulgent Genetics, Inc. FLGT Therapeutic Development — Investment Income Interest

Other segment segments

Laboratory Services
$8.65M+7.9%

Similar metrics at other companies

Dillards logo
DDSConstruction — Investment Income Interest
$220K+4.8%
Lifevantage Corporation logo
LFVNReportable — Investment Income Interest
$35K-74.8%
PCS
PCSCPerceptive — Investment Income Interest
$807.09K-13.6%
KRAKacquisition logo
KRAQSingle — Investment Income Interest
$2.05M—
Strattec Security logo
STRTReportable — Investment Income Interest
-$879K-66.2%
Village Farms International, Inc. logo
VFFCannabis — Investment Income Interest
$192K+131%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$526.64M-16.5%
Enterprise value$511.45M-6.7%
P/S1.6×-0.4×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%—

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0×0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed
May 1, 2026, 7:08 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-199065
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Laboratory services
Interest income$8,651$8,018
Interest expense(17)(14)
Therapeutic development
Interest income——
Interest expense——
Total$8,634$8,004

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s therapeutic development — investment income interest?
Fulgent Genetics, Inc. (FLGT) reported therapeutic development — investment income interest of $0 in Q1 2026.
What does therapeutic development — investment income interest mean?
This captures interest income generated from cash or financial assets specifically allocated to the therapeutic development segment. It provides insight into the segment's ability to generate returns on its available capital resources.

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — investment income interest.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude